We found that BRQ or anti–PD-1 mAb alone had little to no effect on primary tumor growth in these 2 TNBC models (Figure 4, B and C, and Supplemental Figure 4, A and B), consistent with our earlier findings (Figure 3) and prior studies on de novo ICI (anti–PD-1) resistance (50, 52). This evidence concerns the gene PDCD1 and neoplasm.